Reviving the use of aldosterone inhibitors in treating hypertension in obesity

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 309, Issue 9, 2015, Pages R1065-R1067

  Huby, Anne Cecile ^a   Belin de Chantemèle, Eric J ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Aldosterone; Hypertension; Obesity

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR;

ANTIHYPERTENSIVE THERAPY; CLINICAL EFFECTIVENESS; HORMONE INHIBITION; HUMAN; HYPERTENSION; OBESITY; PRIORITY JOURNAL; RESISTANT HYPERTENSION; REVIEW; ANIMAL; BIOLOGICAL MODEL; COMPLICATION; EVIDENCE BASED MEDICINE; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; TREATMENT OUTCOME;

ALDOSTERONE; ANIMALS; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; OBESITY; RECEPTORS, MINERALOCORTICOID; TREATMENT OUTCOME;

EID: 84946032137     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00133.2015     Document Type: Review

References (25)

1. ALLHAT Officers, and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997, 2002.
2. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, Shamlaye C, Burnier M. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48: 239-245, 2006.
3. Bramlage P, Pittrow D, Wittchen HU, Kirch W, Boehler S, Lehnert H, Hoefler M, Unger T, Sharma AM. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 17: 904-910, 2004.
4. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Corrâ JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus, associated obesity and vascular dysfunction. Hypertension 59: 1069-1078, 2012.
5. Byrd JB, Brook RD. A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesityassociated hypertension. J Hum Hypertens 28: 3-9, 2014.
6. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2: 462-468, 2008.
7. Caprio M, Fève B, Claës A, Viengchareun S, Lombès M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroidinduced adipogenesis. FASEB J 21: 2185-2194, 2007.
8. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49: 839-845, 2007.
9. Costa MB, Andrade Ezequiel DG, Morais Lovis JC, Oliveira MM, Baumgratz de Paula R. Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome. J Clin Hypertens (Greenwich) 12: 753-755, 2010.
10. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 4: 393-404, 2002.
11. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 55: 147-152, 2010.
12. Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich) 13: 644-648, 2011.
13. Garrison RJ, Kannel WB, Stokes J, 3rd, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 16: 235-251, 1987.
14. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 43: 518-524, 2004.
15. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 7: 355-362, 1999.
16. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesityinduced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 116: 991-1006, 2015.
17. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 30: 418-424, 2009.
18. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 42: 878-884, 2003.
19. Pimenta E, Gaddam KK, Oparil S. Mechanisms and treatment of resistant hypertension. J Clin Hypertens (Greenwich) 10: 239-244, 2008.
20. Saha C, Eckert GJ, Ambrosius WT, Chun TY, Wagner MA, Zhao Q, Pratt JH. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 46: 481-487, 2005.
21. Sarzani R, Guerra F, Mancinelli L, Buglioni A, Franchi E, Dessì- Fulgheri P. Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment. Am J Hypertens 25: 818-826, 2012.
22. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 110: 438-441, 2001.
23. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Annals Int Med 150: 776-783, 2009.
24. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 304: 930 -933, 1981.
25. Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, Murabito JM, Sam F, Colucci WS, Wilson PWF. Relations of serum aldosterone to cardiac structure. Hypertension 43: 957-962, 2004.